Table 2

Treatment efficacy of anakinra and canakinumab in patients with MWS

IL-1 inhibitor

Anakinra cohort (n = 12)

Canakinumab cohort (n = 14)


Baseline

Short-term end pointa

Comparison short-term end point, baseline

Long-term end pointb

Comparison long-term end point, baseline

Baseline

Short-term end pointa

Com-parison short-term end point, baseline

Long-term end pointb

Com-parison long-term end point, baseline


Disease activity score (MWS-DAS)


Mean MWS-DAS (stdv)

13 (2.2)

3 (1.0)

0.0005

4 (3.2)

0.0005

6 (1.9)

3 (1.8)

0.002

2 (1.3)

0.0002


Inflammatory markers


Mean ESR in mm/h (stdv)

32 (17)

13 (16)

0.02

10 (5)

0.0005

24 (9.8)

11.9 (4.6)

<0.0001

8.4 (4.8)

<0.0001


Elevated ESR (%)

(>22 mm/h)

9 (75)

1 (8)

-

1 (8)

-

9 (64)

0

1 (7)


Mean CRP in mg/dl (stdv)

2.1 (1.3)

0.9 (1.9)

0.09 NS

0.4 (0.5)

0.0005

2.3 (2.1)

0.1 (0.1)

0.001

0.2 (0.3)

0.001


Elevated CRP (%)

(>0.5 mg/dl)

11 (92)

4 (33)

-

3 (25)

-

12 (86)

0

-

1 (7)

-


Mean SAA in mg/L (stdv)

36.5 (26.1)

27.5 (70.5)

0.67 NS

6.6 (5.2)

0.001

88.4 (185.1)

3.4 (3.8)

0.01

4.50 (5.8)

0.11 NS


Elevated SAA (%)

(>10 mg/L)

11 (92)

4 (33)

-

3 (25)

-

9 (64)

1 (7)

-

1 (7)

-


Mean S100A12 in ng/ml (stdv)

240 (172)

(11/12)

142 (57)

(11/12)

0.05

273 (330)

(11/12)

0.70 NS

284.1

(255.5)

73.4

(51.4)

0.01

76.4

(44.5)

0.01


Elevated S100A12 (%)

(>130 ng/ml)

6/11 (55)

6/11 (55)

-

5/11 (45)

-

10 (71)

1 (7)

-

2 (14)

-


Remission (MWS-DAS ≤5 plus normal CRP and SAA)


Patients in remission (%)

NA

8 (67)

9 (75)

NA

13 (93)

13 (93)


Stdv, standard deviation. aShort-term end point was 14 days for anakinra and 8 days for canakinumab, based on the specific pharmacokinetic features of each drug. bMedian long-term end point was 12 (5 to 14) months for anakinra and 11 (6 to 15) months for canakinumab.

Kuemmerle-Deschner et al. Arthritis Research & Therapy 2013 15:R64   doi:10.1186/ar4237

Open Data